Terns Pharmaceuticals Inc (TERN)

$52.92 -0.25 (-0.47%)
Market Cap 5.49B
Revenue (ttm) 0.00
Net Income (ttm) -88.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 7,923,000
Avg Vol 4,234,436
Day's Range N/A - N/A
Shares Out 103.76M
Stochastic %K 97%
Beta -0.31
Analysts Strong Sell
Price Target $55.44

Company Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 525 5535
Fax: 650 275 4254
Address:
1065 East Hillsdale Boulevard, Suite 100, Foster City, United States
SqueezingBee
SqueezingBee Mar. 30 at 8:09 AM
$BULL $SOUN $TERN $FSLY <<
0 · Reply
DragonAlgo
DragonAlgo Mar. 30 at 12:55 AM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $3.15 Stop: $2.27 TP1: $4.09 TP2: $5.35 TP3: $7.56 Volatility regime is active. 🔗 https://dragonalgo.com
0 · Reply
LisLee
LisLee Mar. 29 at 6:51 PM
$TERN biotech setup with low attention and real asymmetry if volume expands
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 29 at 5:59 PM
$TERN do you know this was sold moron to Mrk
0 · Reply
nevasing88
nevasing88 Mar. 29 at 5:34 PM
$TERN low attention biotech and these can rip hard when buyers finally force a breakout
0 · Reply
InvestKaki
InvestKaki Mar. 29 at 12:00 AM
$BRK.A $OPENAI $MRK $TERN $NVDA https://www.investkaki.com/p/china-no-1-tech-companies
0 · Reply
Szepen
Szepen Mar. 28 at 2:06 PM
$SLS $TERN What about Millennium smartie...very
0 · Reply
PeterRaslow
PeterRaslow Mar. 28 at 1:39 PM
$SLS institutional is super low under 20 percent and no active bio funds even took a starter position this is a scam company only for diluting shares thank you for attention to this matter compare $TERN ownership so sls, day and night sls is a scam, small cherry picked trial that will give both arms a 21 mos
2 · Reply
EscobarrRiches
EscobarrRiches Mar. 28 at 3:18 AM
$TERN 100$ soon i think
1 · Reply
DragonAlgo
DragonAlgo Mar. 27 at 6:24 PM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $3.20 Stop: $2.30 TP1: $4.16 TP2: $5.44 TP3: $7.68 Risk preset by model constraints. 🔗 https://dragonalgo.com
0 · Reply
Latest News on TERN
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst

Mar 25, 2026, 11:20 AM EDT - 4 days ago

Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst

MRK

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

Mar 25, 2026, 7:14 AM EDT - 4 days ago

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

MRK

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma

Mar 25, 2026, 6:51 AM EDT - 4 days ago

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma

MRK

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns

Mar 25, 2026, 6:49 AM EDT - 5 days ago

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns

MRK

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Mar 25, 2026, 6:48 AM EDT - 5 days ago

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

MRK

Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports

Mar 24, 2026, 9:14 PM EDT - 5 days ago

Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports

MRK

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Feb 25, 2026, 4:05 PM EST - 4 weeks ago

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Feb 2, 2026, 4:05 PM EST - 7 weeks ago

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 2 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 9:15 PM EST - 2 months ago

Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 4:05 PM EST - 2 months ago

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Terns CEO Amy Burroughs talks cancer drug trial win

Dec 15, 2025, 6:31 PM EST - 3 months ago

Terns CEO Amy Burroughs talks cancer drug trial win

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 11, 2025, 4:05 PM EST - 3 months ago

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Terns Announces Pricing of Upsized $650 Million Public Offering

Dec 9, 2025, 11:30 PM EST - 3 months ago

Terns Announces Pricing of Upsized $650 Million Public Offering

Cancer Study Buoys These Small Biotechs

Dec 9, 2025, 3:31 PM EST - 3 months ago

Cancer Study Buoys These Small Biotechs

ACLX LEGN

Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again

Dec 9, 2025, 2:34 PM EST - 3 months ago

Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again

Terns Announces Proposed Public Offering

Dec 9, 2025, 6:12 AM EST - 3 months ago

Terns Announces Proposed Public Offering

Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript

Dec 8, 2025, 11:27 PM EST - 3 months ago

Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Dec 8, 2025, 2:45 PM EST - 3 months ago

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

Nov 14, 2025, 4:05 PM EST - 4 months ago

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 10, 2025, 4:05 PM EST - 4 months ago

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades

Nov 3, 2025, 1:05 PM EST - 5 months ago

Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Nov 3, 2025, 9:05 AM EST - 5 months ago

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?

Oct 22, 2025, 2:43 PM EDT - 5 months ago

Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?

Terns Pharma ends obesity drug program after mid-stage trial data

Oct 21, 2025, 4:56 PM EDT - 5 months ago

Terns Pharma ends obesity drug program after mid-stage trial data

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Oct 21, 2025, 4:05 PM EDT - 5 months ago

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 12:13 PM EDT - 7 months ago

Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript

Sep 3, 2025, 11:33 PM EDT - 7 months ago

Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Aug 21, 2025, 4:05 PM EDT - 7 months ago

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 4:05 PM EDT - 8 months ago

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts

Jul 11, 2025, 11:27 AM EDT - 9 months ago

Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Jun 23, 2025, 4:07 PM EDT - 9 months ago

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 29, 2025, 4:05 PM EDT - 10 months ago

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

May 14, 2025, 9:30 AM EDT - 11 months ago

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 8, 2025, 4:05 PM EDT - 11 months ago

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Apr 30, 2025, 4:05 PM EDT - 11 months ago

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Feb 26, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 8:05 AM EST - 1 year ago

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Feb 24, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Feb 20, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Feb 3, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Terns's stock soars as analysts cheer leukemia data — and predict more gains

Dec 4, 2024, 1:18 PM EST - 1 year ago

Terns's stock soars as analysts cheer leukemia data — and predict more gains

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Dec 3, 2024, 8:01 AM EST - 1 year ago

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

SqueezingBee
SqueezingBee Mar. 30 at 8:09 AM
$BULL $SOUN $TERN $FSLY <<
0 · Reply
DragonAlgo
DragonAlgo Mar. 30 at 12:55 AM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $3.15 Stop: $2.27 TP1: $4.09 TP2: $5.35 TP3: $7.56 Volatility regime is active. 🔗 https://dragonalgo.com
0 · Reply
LisLee
LisLee Mar. 29 at 6:51 PM
$TERN biotech setup with low attention and real asymmetry if volume expands
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 29 at 5:59 PM
$TERN do you know this was sold moron to Mrk
0 · Reply
nevasing88
nevasing88 Mar. 29 at 5:34 PM
$TERN low attention biotech and these can rip hard when buyers finally force a breakout
0 · Reply
InvestKaki
InvestKaki Mar. 29 at 12:00 AM
$BRK.A $OPENAI $MRK $TERN $NVDA https://www.investkaki.com/p/china-no-1-tech-companies
0 · Reply
Szepen
Szepen Mar. 28 at 2:06 PM
$SLS $TERN What about Millennium smartie...very
0 · Reply
PeterRaslow
PeterRaslow Mar. 28 at 1:39 PM
$SLS institutional is super low under 20 percent and no active bio funds even took a starter position this is a scam company only for diluting shares thank you for attention to this matter compare $TERN ownership so sls, day and night sls is a scam, small cherry picked trial that will give both arms a 21 mos
2 · Reply
EscobarrRiches
EscobarrRiches Mar. 28 at 3:18 AM
$TERN 100$ soon i think
1 · Reply
DragonAlgo
DragonAlgo Mar. 27 at 6:24 PM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $3.20 Stop: $2.30 TP1: $4.16 TP2: $5.44 TP3: $7.68 Risk preset by model constraints. 🔗 https://dragonalgo.com
0 · Reply
Stonski
Stonski Mar. 27 at 4:34 PM
$SLS ooh n yall bears are soo fucking STUPID man .. get a life !! Cos when this pulls that’s $TERN MOVE will will see who get the LAST LAUGH .. fucking idiots !!
1 · Reply
shopno
shopno Mar. 27 at 11:53 AM
$SLS $TERN I forgot mentioning --- but that's the only thing I could think of. So concur your point. Particularly GPS with a P3 trial delivering HR in 0.3-0.4 would seal the deal. Unlike SLS009 for R/R AML where patients mOS < 1 year, in CR2 maintenance patients may stay on GPS average 3-4 years, and in CR1 average 5-6 years (in P2 they had 5.5 years mOS for CR1 setting). Such long mOS and best-in-class therapy for both CR1/2 approval potentially can boost peak GPS TAM $5B+ in US alone. All in all global TAM could be $10B+ for SLS.
0 · Reply
Bobdavis543211
Bobdavis543211 Mar. 27 at 11:50 AM
$SLS the difference between $TERN and sls is this SLS has barely 20 percent and Tern has active bio funds and sls has zero bio funds one is real and one is a fraud ask yourself how a p1 got 7 billion with over 100 percent ownership and GPS blockbuster is barely 20 percent and no offers, no placements , no interest but only from the internet retail crowd typing BO 24/7 1 is real and 1 is fake
0 · Reply
De12
De12 Mar. 27 at 11:41 AM
$SLS $TERN got 6.7 Billion for CML What will $SLS get for AML which has 22,000 new cases /year
0 · Reply
shopno
shopno Mar. 27 at 8:26 AM
$SLS $TERN any thoughts why TERN got only $6.7B offer with $1B cash on hand and TAM is in $3-6B range? BTW, I am deep in SLS as largest binary pick.
4 · Reply
moneydrip
moneydrip Mar. 27 at 4:40 AM
$SLS $TERN
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Mar. 27 at 3:31 AM
$SLS look at $TERN Their leading obesity drug failed, they released the data, dropped to 6 then ripped to 40s. Cancer vaccines is the future of maintenance therapy. GPS will very likely succeed, in the rate event that it fails, the next drug up will eventually succeed. Triple digits coming.
2 · Reply
ians
ians Mar. 26 at 7:46 PM
$VKTX $TGTX could be next🤞 MRK BO of $TERN for $6.7B JUST provided another M&A comp. $7-15B BO ranges are reasonable valuations. JUST look at '25 BO targets. And we all know BP is hungry to fill up that patent cliff gap 😉☘️💎
1 · Reply
ians
ians Mar. 26 at 7:42 PM
$VSTM $IOVA $AMRN Green in a bloodbath☘️ MRK BO of $TERN for $6.7B JUST provided another M&A comp. Any of the tickers above could be next. And we all know BP is hungry to fill up that patent cliff gap 😉☘️💎
0 · Reply
_TP888
_TP888 Mar. 26 at 6:24 PM
$TERN | $47.00 | Put | Premium: $106K Nearly all ask-side - put buyers swept the offer. Fast fill at the ask.
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 26 at 4:31 PM
$SLS $MRK the $IMGN $ABBV - $10.1B Buyout for Elahere is a $10.1B Comp for GPS - $10B Just for Platinum Resistant Ovarian Cancer. - Elahere achieved a MOS of 16.46 Months, with Some Severe Side Effects, actually Blinds Patients. Gps + Key MOS of 18.4 Months is better, with Zero Additional Toxicity. - $TERN $6.7B Buyout is a Direct Comp just for SLS009 - Phase 2B Data Presented at ASH Dec 2025 for AML High-Risk TP53/ASXL1+ ... SLS Shares Sub $40 represents the Investment Opportunity of a Lifetime. ALL Gps needs for Fda Approval, per the Pre Approved SAP, is a HR of .636 and its a done deal.
0 · Reply
TeresaTrades
TeresaTrades Mar. 26 at 1:22 PM
Largest CALL OI increases $TERN $ACHR $TSLA $MARA $BYND
0 · Reply